Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations

European Journal of Nuclear Medicine

Volumn 25, Issue 2, 1998, Pages 201-212

  Behr, Thomas M ^a,b   Goldenberg, David M ^b   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibody fragments; Cationic amino acids; Lysine; Peptides; Radiation nephrotoxicity; Renal uptake

Indexed keywords

AMINO ACID; AMINOSUGAR; ANTIBODY; ANTIBODY CONJUGATE; IMMUNOGLOBULIN F(AB) FRAGMENT; LYSINE; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

CANCER THERAPY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY TUBULE ABSORPTION; METHODOLOGY; MOLECULAR WEIGHT; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; URINALYSIS;

AMINO ACIDS; ANIMALS; ANTIBODIES; CLINICAL TRIALS; FORECASTING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KIDNEY; PEPTIDES; RADIATION DOSAGE; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS;

EID: 0031911476     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050216     Document Type: Review

References (41)

1. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36:430-441.
2. 99mTc: the role of metabolism and kinetics. Cancer Res 1995; 55:5777s-5785s.
3. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PPM, Lamberts SWJ. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993; 20: 283-292.
4. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hör G. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 1994; 73: 896-899.
5. Blumenthal RD, Sharkey RM, Goldenberg DM. Overcoming dose-limiting, radioantibody-induced myelotoxicity. In: Goldenberg DM, ed., Cancer therapy with radiolabeled antibodies. Boca Raton: CRC Press; 1995: 295-314.
6. Larson SM, Carrasquillo JA, McGuffm RW, Krohn KA, Ferens JM, Hill LD, Beaumier PL, Reynolds JC, Hellström KE. Hellström I. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 1985; 155: 487-492.
7. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24: 368-371.
8. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997; 41:63-70.
9. Morgenson CE, Sølling K. Studies on renal tubular protein re-absorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 37: 477-486.
10. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev 1988; 68: 912-986.
11. Maack T, Johnson V, Kan ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low molecular weight proteins: a review. Kidney Int 1979; 16: 251-270.
12. Sharkey RM, Behr, TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 44: 179-188.
13. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung. J Nucl Med 1997; 38: 391-395.
14. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins. J Nucl Med 1993; 34: 1728-1738.
15. Duncan JR, Behr TM, DeNardo S. Intracellular fate of radiometals. J Nucl Med 1997; 38: 829.
16. Ryan R, McNeil JS, Flamenbaum W, Nagle R. Uranyl nitrate induced renal failure in the rat: effect of varying doses and saline loading. Proc Soc Exp Biol Med 1973; 143: 289-296.
17. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, Bloom SR, Calam J. Amino acid infusion blocks renal tubular uptake of indium-labelled somatostatin analogue. Br J Cancer 1993; 67: 1437-1439.
18. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 1994; 21: 663-665.
19. Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990; 31: 1510-1519.
20. Tarburton JP, Halpern SE, Hagan PL, Sudora E, Chen A, Fridman DM, Pfaff AE. Effect of acetylation on monoclonal antibody ZCE-025 Fab′: distribution in normal and tumor-bearing mice. J Biol Response Mod 1990; 9: 221-230.
21. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Bair HJ, Griffiths GL, Wolf FG, Becker WS, Goldenberg DM. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55: 3825-3834.
22. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? J Nucl Med 1996; 37: 834-836.
23. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. Reduction of the renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996; 37: 829-833.
24. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths G, Siegel JA, Becker WS, Goldenberg DM. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997; 80: 2591-2610.
25. Carrasquillo JA, Lang L, Whatley M, Herscovitch P, Wang, QC, Pastan I, Eckelman WC. Use of a commercially available amino acid solution to block renal uptake of F-18 fluoromethylbenzoyl (FMB)-dsFv [abstract]. J Nucl Med 1997; 38: 10P.
26. 177Lu]α-[2-(4-aminophenyl)ethyl]-l,4,7,10-tetraaza-cyclodecane- l,4,7,10-tetraacetic acid-CC49 Fab radioimmuno-conjugate. Cancer Res 1995; 55: 5288-5295.
27. 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 1996; 56:3788-3795.
28. DeJong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WAP, Krenning EP. Inhibition of the renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37:1388-1392.
29. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med 1995; 22: 608-616.
30. 90Y-Dosimetry in the nude mouse: evaluation of three dosimetry models in relation to the observed biological effects in the radioimmunotherapy of human colon cancer xenografts. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium in Gatlinburg, TN, 1996 (in press).
31. Zager RA. Amino acid hyperalimentation in acute renal failure: a potential therapeutic paradox. Kidney Int 1987; 32 (Suppl): S72-S75.
32. Zager RA, Johannes G, Tuttle SE, Sharma HM. Acute amino acid nephrotoxicity. J Lab Clin Med 1983; 101: 130-140.
33. Abel RM, Beck CH, Abbott WM, Ryan JA, Barnett GO, Fischer JE. Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose. Results of a prospective, double-blind study. N Engl J Med 1973; 288: 695-699.
34. Dancis J, Hutzler J, Ampoia MG, Shih VE, van Gelderen HH, Kirby LT, Woody NC. The prognosis of hyperlysinemia: an interim report. Am J Genet 1983; 35: 438-442.
35. Hendry JH, Lord BI, eds. Radiation toxicology: bone marrow and leukaemia. London: Taylor & Francis, 1995.
36. Blumenthal RD, Sharkey RM, Forman D, Wong G, Hess J, Goldenberg DM. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp Hematol 1995; 23: 1088-1097.
37. Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor-efficacy. Submitted for publication, 1997.
38. Pearse HD. The kidney. In: Cox JD, ed. Moss' radiation oncology - rationale, technique, results. St. Louis: Mosby; 1994: 499-517.
39. Luxton RW. Radiation nephritis - A long-term study of 54 patients. Lancet 1961; II: 1221-1224.
40. Madrazo AA, Churg J. Radiation nephritis - chronic changes following moderate doses of radiation. Lab Invest 1976; 34: 283-290.
41. Despopoulos A, Silbernagl S. Color atlas of physiology. Stuttgart: Thieme; 1991: 129.